首页 > 最新文献

Journal of pharmacological and toxicological methods最新文献

英文 中文
Drug combination assays using Caenorhabditis elegans as a model system
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-02-01 DOI: 10.1016/j.vascn.2025.107583
Guillermina Hernando, Cecilia Bouzat
The C. elegans drug combination assay evaluates the effects of drug combinations in the nematode Caenorhabditis elegans, serving as a valuable tool to assess the efficacy of pharmaceutical agents and natural compounds. Using C. elegans as a model organism, this method allows for the efficient screening of the combined effects of different drugs and evaluation of synergistic effects in drug combinations, which reduces the risk of developing drug resistance.
Combination therapy, involving commercial drugs, new agents, or natural products, broadens treatment effectiveness by targeting multiple pathways, effectively managing complex diseases with minimized side effects. The method focuses on discovering effective drug combinations, such as anthelmintic drugs, streamlining early-stage drug discovery to save time and resources. Additionally, its versatility allows for application across most areas of pharmacology and toxicology, extending its usefulness beyond anthelmintic treatments.
In the experiments, synchronized worms are exposed to different drug concentrations to evaluate behavioral changes, mostly alterations in worm locomotion. Concentration-response curves for changes in behavior are generated and EC50 or IC50 values determined for the individual drugs. To determine whether the effects of a drug combination are synergistic, additive, or antagonistic, at least three different concentration ratios must be tested. These combinations are then analyzed using specialized drug combination analysis software. This methodology ensures consistent and precise outcomes and evaluates drug impacts on worm behavior parameters crucial for effective pharmacological activity.
In conclusion, the C. elegans drug combination assay provides critical insights for developing successful market formulations applicable across a wide range of pharmacological treatments. Its ability to efficiently screen for synergistic, additive, or antagonistic effects makes it a valuable tool for identifying effective therapeutic strategies, potentially reducing drug resistance and improving treatment outcomes in various medical and toxicological fields.
{"title":"Drug combination assays using Caenorhabditis elegans as a model system","authors":"Guillermina Hernando,&nbsp;Cecilia Bouzat","doi":"10.1016/j.vascn.2025.107583","DOIUrl":"10.1016/j.vascn.2025.107583","url":null,"abstract":"<div><div>The <em>C. elegans</em> drug combination assay evaluates the effects of drug combinations in the nematode <em>Caenorhabditis elegans</em>, serving as a valuable tool to assess the efficacy of pharmaceutical agents and natural compounds. Using <em>C. elegans</em> as a model organism, this method allows for the efficient screening of the combined effects of different drugs and evaluation of synergistic effects in drug combinations, which reduces the risk of developing drug resistance.</div><div>Combination therapy, involving commercial drugs, new agents, or natural products, broadens treatment effectiveness by targeting multiple pathways, effectively managing complex diseases with minimized side effects. The method focuses on discovering effective drug combinations, such as anthelmintic drugs, streamlining early-stage drug discovery to save time and resources. Additionally, its versatility allows for application across most areas of pharmacology and toxicology, extending its usefulness beyond anthelmintic treatments.</div><div>In the experiments, synchronized worms are exposed to different drug concentrations to evaluate behavioral changes, mostly alterations in worm locomotion. Concentration-response curves for changes in behavior are generated and EC<sub>50</sub> or IC<sub>50</sub> values determined for the individual drugs. To determine whether the effects of a drug combination are synergistic, additive, or antagonistic, at least three different concentration ratios must be tested. These combinations are then analyzed using specialized drug combination analysis software. This methodology ensures consistent and precise outcomes and evaluates drug impacts on worm behavior parameters crucial for effective pharmacological activity.</div><div>In conclusion, the <em>C. elegans</em> drug combination assay provides critical insights for developing successful market formulations applicable across a wide range of pharmacological treatments. Its ability to efficiently screen for synergistic, additive, or antagonistic effects makes it a valuable tool for identifying effective therapeutic strategies, potentially reducing drug resistance and improving treatment outcomes in various medical and toxicological fields.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"131 ","pages":"Article 107583"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting clinical outcomes from off-target receptor interactions using Secondary Intelligence™ 利用 Secondary Intelligence™ 从脱靶受体相互作用中预测临床结果。
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-02-01 DOI: 10.1016/j.vascn.2024.107570
Will S. Redfern , Chris E. Pollard , Mark Holbrook , Barira Islam , Mitra Abbasi , Joanne Mahmud , Katie Lambert , Augustus Haslam , Heeseung Jo , Hiba Khalidi , Zofia Bielecka , Josh Starkey , Thomas Ellinger , Simon Bryan , Angeli Savas , Steve Andrews , Rob Aspbury , Lyn Rosenbrier Ribeiro , Kim A. Henderson Park , Hugo M. Vargas , Clare R. Gilmer
Adverse effects due to off-target activity can be predicted by careful comparison of the relationship between expected plasma concentration and off-target activity of the test compound with that of reference drugs targeting that receptor for their therapeutic efficacy. The ratio between plasma concentration (unbound) and the Ki at the receptor is a surrogate measure reflecting receptor occupancy. Where data are available for reference drugs, we have curated and evaluated this at 100 receptors, 72 of which can involve both negative and positive modulations by drugs: a total of 172 ‘receptor modulations’. This provides a quantitative framework upon which to achieve consistent risk assessment of off-target interactions across receptors, across compounds and between assessors. It therefore represents a significant departure from an opinion-based to an evidence-based approach to secondary pharmacology. Demonstration of proof-of-principle was achieved for one of the receptor interactions (α1A-adrenoceptor antagonism leading to postural hypotension in clinical use) due to the availability of high-quality off-target Ki data for >30 drugs at this receptor.
通过仔细比较受试化合物的预期血浆浓度和脱靶活性与针对该受体发挥疗效的参考药物的预期血浆浓度和脱靶活性之间的关系,可以预测脱靶活性导致的不良反应。血浆浓度(未结合)与受体 Ki 之间的比值是反映受体占用率的代用指标。在有参考药物数据的情况下,我们对 100 种受体进行了整理和评估,其中 72 种受体可能同时受到药物的负向和正向调节:共计 172 种 "受体调节"。这提供了一个定量框架,在此基础上可对不同受体、不同化合物和不同评估者之间的脱靶相互作用进行一致的风险评估。因此,它实现了二级药理学方法从基于观点到基于证据的重大转变。对其中一种受体相互作用(α1A-肾上腺素受体拮抗作用导致临床应用中的体位性低血压)进行了原则性论证,因为在该受体上有超过 30 种药物的高质量脱靶 Ki 数据。
{"title":"Predicting clinical outcomes from off-target receptor interactions using Secondary Intelligence™","authors":"Will S. Redfern ,&nbsp;Chris E. Pollard ,&nbsp;Mark Holbrook ,&nbsp;Barira Islam ,&nbsp;Mitra Abbasi ,&nbsp;Joanne Mahmud ,&nbsp;Katie Lambert ,&nbsp;Augustus Haslam ,&nbsp;Heeseung Jo ,&nbsp;Hiba Khalidi ,&nbsp;Zofia Bielecka ,&nbsp;Josh Starkey ,&nbsp;Thomas Ellinger ,&nbsp;Simon Bryan ,&nbsp;Angeli Savas ,&nbsp;Steve Andrews ,&nbsp;Rob Aspbury ,&nbsp;Lyn Rosenbrier Ribeiro ,&nbsp;Kim A. Henderson Park ,&nbsp;Hugo M. Vargas ,&nbsp;Clare R. Gilmer","doi":"10.1016/j.vascn.2024.107570","DOIUrl":"10.1016/j.vascn.2024.107570","url":null,"abstract":"<div><div>Adverse effects due to off-target activity can be predicted by careful comparison of the relationship between expected plasma concentration and off-target activity of the test compound with that of reference drugs targeting that receptor for their therapeutic efficacy. The ratio between plasma concentration (unbound) and the K<sub>i</sub> at the receptor is a surrogate measure reflecting receptor occupancy. Where data are available for reference drugs, we have curated and evaluated this at 100 receptors, 72 of which can involve both negative and positive modulations by drugs: a total of 172 ‘receptor modulations’. This provides a quantitative framework upon which to achieve consistent risk assessment of off-target interactions across receptors, across compounds and between assessors. It therefore represents a significant departure from an opinion-based to an evidence-based approach to secondary pharmacology. Demonstration of proof-of-principle was achieved for one of the receptor interactions (α<sub>1A</sub>-adrenoceptor antagonism leading to postural hypotension in clinical use) due to the availability of high-quality off-target K<sub>i</sub> data for &gt;30 drugs at this receptor.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"131 ","pages":"Article 107570"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of a sensitive LC-MS/MS assay for determination of upadacitinib in human plasma and its application in patients with inflammatory bowel disease
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-02-01 DOI: 10.1016/j.vascn.2025.107581
Jing-jing Wu , Lang Lin , Jia-jia Yan , Jia-he Kong , Qiao-lan Xuan , Xiang Gao , Kang Chao , Xia Zhu

Background

Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor approved by the Food and Drug Administration for the treatment of moderate-to-severe inflammatory bowel disease (IBD). We aimed to establish and validate a method for determining Upadacitinib in patients with IBD by liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.

Methods

The mobile phase was 0.1 % formic acid: acetonitrile (35:65, v/v) at a flow rate of 0.40 mL/min. Upadacitinib and its internal standard Upadacitinib 15N, d2 were separated by a Waters Xbridge BEH C18 column (4.6 × 100 mm, 2.5 μm) and subjected to mass analysis using positive electrospray ionization (ESI).

Results

The calibration range of Upadacitinib was 0.5–200 ng/mL with the correlation coefficient r2 ≥ 0.99. Accuracies ranged from −9.48 % ∼ 8.27 % and the inter- and intra-day precisions were less than 15 % for all analytes in quality control samples. There was no significant matrix effect. The range of extraction recoveries was 87.53–93.47 % for all analytes. Twenty-one plasma samples were obtained from the sixth affiliated hospital of Sun Yat-sen University. The median plasma concentration of Upadacitinib was 7.32 (0.56–26.78) ng/mL.

Conclusion

This newly developed method is sensitive, simple, and successfully applied in determining Upadacitinib in IBD patients to provide reference for safe and effective drug administration in clinical practice.
{"title":"Development and validation of a sensitive LC-MS/MS assay for determination of upadacitinib in human plasma and its application in patients with inflammatory bowel disease","authors":"Jing-jing Wu ,&nbsp;Lang Lin ,&nbsp;Jia-jia Yan ,&nbsp;Jia-he Kong ,&nbsp;Qiao-lan Xuan ,&nbsp;Xiang Gao ,&nbsp;Kang Chao ,&nbsp;Xia Zhu","doi":"10.1016/j.vascn.2025.107581","DOIUrl":"10.1016/j.vascn.2025.107581","url":null,"abstract":"<div><h3>Background</h3><div>Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor approved by the Food and Drug Administration for the treatment of moderate-to-severe inflammatory bowel disease (IBD). We aimed to establish and validate a method for determining Upadacitinib in patients with IBD by liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.</div></div><div><h3>Methods</h3><div>The mobile phase was 0.1 % formic acid: acetonitrile (35:65, <em>v</em>/v) at a flow rate of 0.40 mL/min. Upadacitinib and its internal standard Upadacitinib <img><sup>15</sup>N, d<sub>2</sub> were separated by a Waters Xbridge BEH C18 column (4.6 × 100 mm, 2.5 μm) and subjected to mass analysis using positive electrospray ionization (ESI).</div></div><div><h3>Results</h3><div>The calibration range of Upadacitinib was 0.5–200 ng/mL with the correlation coefficient r<sup>2</sup> ≥ 0.99. Accuracies ranged from −9.48 % ∼ 8.27 % and the inter- and intra-day precisions were less than 15 % for all analytes in quality control samples. There was no significant matrix effect. The range of extraction recoveries was 87.53–93.47 % for all analytes. Twenty-one plasma samples were obtained from the sixth affiliated hospital of Sun Yat-sen University. The median plasma concentration of Upadacitinib was 7.32 (0.56–26.78) ng/mL.</div></div><div><h3>Conclusion</h3><div>This newly developed method is sensitive, simple, and successfully applied in determining Upadacitinib in IBD patients to provide reference for safe and effective drug administration in clinical practice.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"131 ","pages":"Article 107581"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Compromising the immunogenicity of diphtheria toxin-based immunotoxins through epitope engineering: An in silico approach 通过表位工程降低白喉毒素免疫毒素的免疫原性:一种计算机方法。
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-02-01 DOI: 10.1016/j.vascn.2024.107571
Behrouz Golichenari , Mohammad Heiat , Ehsan Rezaei , Amirreza Ramshini , Amirhossein Sahebkar , Nazila Gholipour
Immunotoxins are genetically engineered recombinant proteins consisting of a targeting moiety, such as an antibody, and a cytotoxic toxin moiety of microbial origin. Pseudomonas exotoxin A and diphtheria toxin (DT) have been abundantly used in immunotoxins, with the latter applied as the toxin moiety of the FDA-approved drug Denileukin diftitox (ONTAK®). However, the use of immunotoxins provokes an adverse immune response in the host body against the toxin moiety, limiting their efficacy. In silico approaches have received increasing attention in protein engineering. In this study, the epitopes responsible for immunogenicity were identified through multiple platforms. By subtracting conserved and ligand-binding residues, K33, T111, and E112 were identified as common epitopes across all platforms. Substitution analysis evaluated alternative residues regarding their impact on protein stability, considering 19 different amino acid substitutions. Among the mutants explored, the T111A-E112G mutant exhibited the most destabilizing substitution for DT, thereby reducing immunogenicity. Finally, a 3D model of the mutant was generated and verified. The model was then docked with its native ligand NADH, and the complex's molecular behavior was simulated using molecular dynamics.
免疫毒素是由靶向片段(如抗体)和微生物来源的细胞毒素片段组成的基因工程重组蛋白。假单胞菌外毒素A和白喉毒素(DT)已被广泛用于免疫毒素中,后者被用作fda批准的药物Denileukin diftitox (ONTAK®)的毒素部分。然而,免疫毒素的使用引起宿主体内对毒素部分的不良免疫反应,限制了它们的功效。计算机方法在蛋白质工程中受到越来越多的关注。在本研究中,通过多种平台鉴定了负责免疫原性的表位。通过减去保守残基和配体结合残基,K33、T111和E112被鉴定为所有平台上的共同表位。取代分析评估了替代残基对蛋白质稳定性的影响,考虑了19种不同的氨基酸取代。在所研究的突变体中,T111A-E112G突变体表现出最不稳定的DT替代,从而降低了免疫原性。最后,生成突变体的三维模型并进行验证。然后将该模型与其天然配体NADH对接,利用分子动力学模拟该配合物的分子行为。
{"title":"Compromising the immunogenicity of diphtheria toxin-based immunotoxins through epitope engineering: An in silico approach","authors":"Behrouz Golichenari ,&nbsp;Mohammad Heiat ,&nbsp;Ehsan Rezaei ,&nbsp;Amirreza Ramshini ,&nbsp;Amirhossein Sahebkar ,&nbsp;Nazila Gholipour","doi":"10.1016/j.vascn.2024.107571","DOIUrl":"10.1016/j.vascn.2024.107571","url":null,"abstract":"<div><div>Immunotoxins are genetically engineered recombinant proteins consisting of a targeting moiety, such as an antibody, and a cytotoxic toxin moiety of microbial origin. <em>Pseudomonas</em> exotoxin A and diphtheria toxin (DT) have been abundantly used in immunotoxins, with the latter applied as the toxin moiety of the FDA-approved drug Denileukin diftitox (ONTAK®). However, the use of immunotoxins provokes an adverse immune response in the host body against the toxin moiety, limiting their efficacy. <em>In silico</em> approaches have received increasing attention in protein engineering. In this study, the epitopes responsible for immunogenicity were identified through multiple platforms. By subtracting conserved and ligand-binding residues, K33, T111, and E112 were identified as common epitopes across all platforms. Substitution analysis evaluated alternative residues regarding their impact on protein stability, considering 19 different amino acid substitutions. Among the mutants explored, the T111A-E112G mutant exhibited the most destabilizing substitution for DT, thereby reducing immunogenicity. Finally, a 3D model of the mutant was generated and verified. The model was then docked with its native ligand NADH, and the complex's molecular behavior was simulated using molecular dynamics.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"131 ","pages":"Article 107571"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Demonstrating the statistical and pharmacological sensitivity of nonclinical QTc analysis using a dofetilide dose–response in nonhuman primates 利用多非利特在非人灵长类动物中的剂量反应,展示非临床 QTc 分析的统计和药理敏感性。
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-02-01 DOI: 10.1016/j.vascn.2024.107572
Derek J. Leishman , David L. Holdsworth , Derek D. Best , Matthew M. Abernathy , Brian M. Roche
Nonclinical QTc studies can augment clinical QTc assessments in regulatory submissions provided they are of sufficient quality and sensitivity. Both the statistical performance and species translation play a role in determining the sensitivity of the model.
The current analyses examine the effects of dofetilide or vehicle on the QT interval in nonhuman primate (NHP; n = 16) using a one-step estimated marginal means method where both treatment and animal ID are used in regression models to avoid a separate rate correction step, in comparison to other commonly utilized methods. The doses of dofetilide were chosen to span a threshold dose with exposure only just exceeding the concentration associated with 10 ms QTc prolongation in man, to a dose where exposures exceed the Emax for QTc prolongation. The primary objective was an evaluation of which doses and exposures can be detected as eliciting a statistically significant change in QTc.
A group size of 8 for cross-over analysis was insufficient to detect, as statistically significant, the effects of the threshold dose of 0.01 mg/kg dofetilide using common correction and statistical analysis methods and hourly time intervals. Higher doses were all detected as causing a statistically significant effect using the same techniques. The ‘One-Step’ method was able to detect as statistically significant effects at all doses of dofetilide across a wide range of time and exposure. There were also temporal differences between the mean effects observed using the common and ‘One-Step’ methods. Preliminary concentration-QTc assessment suggests a higher maximum prolongation in concentration QTc with the ‘One-Step’ method. Furthermore, this analysis suggests that at exposures associated with a 10 ms QTc prolongation in man a 10 ms prolongation is also observed in NHP. The observed ED50 concentration (0.85 ng/ml unbound) is close to that described in man (0.98 ng/ml).
These analyses demonstrate the statistical sensitivity of the ‘One-Step’ method of QTc assessment in NHP. The pharmacological sensitivity was also demonstrated and a detection threshold of 10 ms was consistent in terms of exposure between NHP and man. Overall, QTc assessment using the ‘One-Step’ method in NHP is a robust and sensitive model to supplement clinical QTc assessment.
如果非临床QTc研究具有足够的质量和敏感性,则可以在提交的监管文件中增强临床QTc评估。统计性能和物种转换都决定了模型的灵敏度。目前的分析研究了多非利特或载药对非人灵长类动物QT间期的影响(NHP;n = 16)使用一步估计边际均值方法,其中回归模型中同时使用治疗和动物ID,与其他常用方法相比,避免了单独的率校正步骤。多非利特的剂量选择跨越阈值剂量,暴露仅略超过与人体10 ms QTc延长相关的浓度,暴露剂量超过QTc延长的Emax。主要目的是评估哪些剂量和暴露可以检测到引起QTc的统计显着变化。采用常规校正和统计分析方法及每小时时间间隔进行交叉分析,8人组不足以检测0.01 mg/kg多非利特阈值剂量的影响,但具有统计学意义。使用相同的技术,更高的剂量都被检测到会产生统计上显著的影响。“一步法”能够在广泛的时间和暴露范围内检测到所有剂量的多非利特的统计显着效应。使用普通方法和“一步法”观察到的平均效应之间也存在时间差异。初步的浓度-QTc评价表明,“一步法”的浓度-QTc的最大延长时间更高。此外,该分析表明,暴露与男性QTc延长10 毫秒有关时,NHP患者也观察到QTc延长10 毫秒。观察到的ED50浓度(0.85 ng/ml未结合)与man(0.98 ng/ml)接近。这些分析证明了“一步法”评估NHP QTc的统计敏感性。药理学敏感性也得到证实,NHP与人类接触的检测阈值为10 ms是一致的。总体而言,在NHP中使用“一步法”进行QTc评估是一种鲁棒且敏感的模型,可以补充临床QTc评估。
{"title":"Demonstrating the statistical and pharmacological sensitivity of nonclinical QTc analysis using a dofetilide dose–response in nonhuman primates","authors":"Derek J. Leishman ,&nbsp;David L. Holdsworth ,&nbsp;Derek D. Best ,&nbsp;Matthew M. Abernathy ,&nbsp;Brian M. Roche","doi":"10.1016/j.vascn.2024.107572","DOIUrl":"10.1016/j.vascn.2024.107572","url":null,"abstract":"<div><div>Nonclinical QTc studies can augment clinical QTc assessments in regulatory submissions provided they are of sufficient quality and sensitivity. Both the statistical performance and species translation play a role in determining the sensitivity of the model.</div><div>The current analyses examine the effects of dofetilide or vehicle on the QT interval in nonhuman primate (NHP; n = 16) using a one-step estimated marginal means method where both treatment and animal ID are used in regression models to avoid a separate rate correction step, in comparison to other commonly utilized methods. The doses of dofetilide were chosen to span a threshold dose with exposure only just exceeding the concentration associated with 10 ms QTc prolongation in man, to a dose where exposures exceed the Emax for QTc prolongation. The primary objective was an evaluation of which doses and exposures can be detected as eliciting a statistically significant change in QTc.</div><div>A group size of 8 for cross-over analysis was insufficient to detect, as statistically significant, the effects of the threshold dose of 0.01 mg/kg dofetilide using common correction and statistical analysis methods and hourly time intervals. Higher doses were all detected as causing a statistically significant effect using the same techniques. The ‘One-Step’ method was able to detect as statistically significant effects at all doses of dofetilide across a wide range of time and exposure. There were also temporal differences between the mean effects observed using the common and ‘One-Step’ methods. Preliminary concentration-QTc assessment suggests a higher maximum prolongation in concentration QTc with the ‘One-Step’ method. Furthermore, this analysis suggests that at exposures associated with a 10 ms QTc prolongation in man a 10 ms prolongation is also observed in NHP. The observed ED<sub>50</sub> concentration (0.85 ng/ml unbound) is close to that described in man (0.98 ng/ml).</div><div>These analyses demonstrate the statistical sensitivity of the ‘One-Step’ method of QTc assessment in NHP. The pharmacological sensitivity was also demonstrated and a detection threshold of 10 ms was consistent in terms of exposure between NHP and man. Overall, QTc assessment using the ‘One-Step’ method in NHP is a robust and sensitive model to supplement clinical QTc assessment.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"131 ","pages":"Article 107572"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ligand-binding assays validated for quantitative bioanalysis of a novel antibody-drug conjugate in monkey serum and related application in a nonclinical study 用于猴血清中新型抗体-药物共轭物定量生物分析的配体结合测定法验证及在非临床研究中的相关应用。
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-02-01 DOI: 10.1016/j.vascn.2024.107580
Yingying Hou , Jie Miao , Yajun Sun , Lili Shi , Lu Ouyang , Xiaoqiang Chen , Ziyi Li , Tingting Liu , Gang Qin , Qiuping Qin , Likun Gong
Background: Antibody-drug conjugates (ADCs) are an emerging class of targeted therapeutics and are receiving growing attention in the pharmaceutical field. Here we aimed to validate two ligand binding assays for the quantitation of GQ1001, an ADC made of Trastuzumab site-specifically conjugated with DM1, in cynomolgus monkey serum, and then apply the validated assays to a nonclinical study. Methods: The quantitative methods for conjugated GQ1001 and total GQ1001 were validated against regulatory guidance documents on bioanalytical method validation under a Good Laboratory Practice (GLP)-compliant environment. The validated assays were applied to a single-dose pharmacokinetic (PK) study of GQ1001 conducted in cynomolgus monkeys. Results: Both intra- and inter-assay precision and accuracy met the priori-defined acceptance criteria. Neither matrix effect nor hemolysis effect were observed, and the impact of specific interferents on the assays was evaluated. Dilution linearity was good with the expected dilution factors and no hook effect till up to 20.2 mg/mL of GQ1001 was noted. Besides, the stability of the ADC in monkey serum was found to be sufficient to cover the time required for sample storage and analysis. Furthermore, the assays demonstrated good parallelism determined with a study sample and good reproducibility acquired by incurred sample reanalysis (ISR). Using the validated assays, we obtained serum concentrations for the conjugated GQ1001 and the total GQ1001 in the single-dose PK study, and thereafter, evaluated their exposures over the dosing period. Conclusions: All tested performance parameters of the assays met the validation acceptance criteria, which supported the application of the two assays in the nonclinical PK study and allowed the evaluation of the related PK parameters for GQ1001.
背景:抗体-药物偶联物(adc)是一类新兴的靶向治疗药物,在制药领域受到越来越多的关注。在这里,我们旨在验证两种配体结合测定法用于定量食食猴血清中GQ1001(一种由曲珠单抗位点特异性结合DM1制成的ADC),然后将验证的测定法应用于非临床研究。方法:在符合良好实验室规范(GLP)的环境下,根据生物分析方法验证的法规指导文件,对偶联GQ1001和总GQ1001的定量方法进行验证。将验证的方法应用于GQ1001在食蟹猴体内的单剂量药代动力学(PK)研究。结果:测定内和测定间的精密度和准确度均满足优先定义的可接受标准。没有观察到基质效应和溶血效应,并评估特异性干扰物对测定的影响。与预期的稀释因子线性良好,在GQ1001浓度达到20.2 mg/mL前无钩效应。此外,发现ADC在猴子血清中的稳定性足以覆盖样品储存和分析所需的时间。此外,测定结果显示了良好的平行性,并通过发生的样品再分析(ISR)获得了良好的再现性。通过验证的方法,我们获得了单剂量PK研究中偶联GQ1001和总GQ1001的血清浓度,然后评估了它们在给药期间的暴露情况。结论:两种检测方法的性能参数均符合验证接受标准,支持两种检测方法在非临床PK研究中的应用,并可对GQ1001的相关PK参数进行评价。
{"title":"Ligand-binding assays validated for quantitative bioanalysis of a novel antibody-drug conjugate in monkey serum and related application in a nonclinical study","authors":"Yingying Hou ,&nbsp;Jie Miao ,&nbsp;Yajun Sun ,&nbsp;Lili Shi ,&nbsp;Lu Ouyang ,&nbsp;Xiaoqiang Chen ,&nbsp;Ziyi Li ,&nbsp;Tingting Liu ,&nbsp;Gang Qin ,&nbsp;Qiuping Qin ,&nbsp;Likun Gong","doi":"10.1016/j.vascn.2024.107580","DOIUrl":"10.1016/j.vascn.2024.107580","url":null,"abstract":"<div><div>Background: Antibody-drug conjugates (ADCs) are an emerging class of targeted therapeutics and are receiving growing attention in the pharmaceutical field. Here we aimed to validate two ligand binding assays for the quantitation of GQ1001, an ADC made of Trastuzumab site-specifically conjugated with DM1, in cynomolgus monkey serum, and then apply the validated assays to a nonclinical study. Methods: The quantitative methods for conjugated GQ1001 and total GQ1001 were validated against regulatory guidance documents on bioanalytical method validation under a Good Laboratory Practice (GLP)-compliant environment. The validated assays were applied to a single-dose pharmacokinetic (PK) study of GQ1001 conducted in cynomolgus monkeys. Results: Both intra- and inter-assay precision and accuracy met the priori-defined acceptance criteria. Neither matrix effect nor hemolysis effect were observed, and the impact of specific interferents on the assays was evaluated. Dilution linearity was good with the expected dilution factors and no hook effect till up to 20.2 mg/mL of GQ1001 was noted. Besides, the stability of the ADC in monkey serum was found to be sufficient to cover the time required for sample storage and analysis. Furthermore, the assays demonstrated good parallelism determined with a study sample and good reproducibility acquired by incurred sample reanalysis (ISR). Using the validated assays, we obtained serum concentrations for the conjugated GQ1001 and the total GQ1001 in the single-dose PK study, and thereafter, evaluated their exposures over the dosing period. Conclusions: All tested performance parameters of the assays met the validation acceptance criteria, which supported the application of the two assays in the nonclinical PK study and allowed the evaluation of the related PK parameters for GQ1001.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"131 ","pages":"Article 107580"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of gene expression change associated with isoflurane anesthesia and neurocognitive disorders using bioinformatics methods
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-30 DOI: 10.1016/j.vascn.2025.107582
Yang Liu , Ying Zhang , Jialu Yu , Hua Fu

Background

Isoflurane, a commonly used anesthetic, has been linked to neurocognitive dysfunction (NCD). However, the precise relationship between isoflurane anesthesia and NCD remains unclear.

Methods

Datasets related to isoflurane anesthesia were obtained from a public database. The hub genes of isoflurane anesthesia were selected using logistic regression with the least absolute shrinkage and selection operator (LASSO). Human neuroblastoma cell line SH-SY5Y was induced to differentiate into terminal neuron-like cells.

Results

The signaling pathways involved in isoflurane anesthesia and NCD were subjected to analysis, resulting in the identification of 35 signaling pathways, including the PI3K/AKT pathway, the AGE-RAGE signaling pathway and the apelin signaling pathway, which were found to be associated with both NCD and isoflurane anesthesia. A total of nine cross-expressed genes (Nfe2l2, Fgf2, Edn1, Spp1, Hmox1, Picalm, Gnb5, Eif2s1 and Gls) were identified between isoflurane anesthesia and NCD. The LASSO logistic regression model was employed to identify three hub genes (Fgf2, Gnb5, Spp1). The expression of these three hub genes was validated using other expression datasets. In human neuron-like cells, isoflurane also significantly affected the expression of three corresponding human homologous genes. The expression trends of these three genes in human cells were consistent with the expression in rat brains after isoflurane treatment, providing further evidence for the rationality of the three hub genes.

Conclusions

The present study revealed key candidate genes and related functional signaling pathways through bioinformatics analysis and cell experiments, which may serve as the basis for isoflurane-related NCD.
{"title":"Identification of gene expression change associated with isoflurane anesthesia and neurocognitive disorders using bioinformatics methods","authors":"Yang Liu ,&nbsp;Ying Zhang ,&nbsp;Jialu Yu ,&nbsp;Hua Fu","doi":"10.1016/j.vascn.2025.107582","DOIUrl":"10.1016/j.vascn.2025.107582","url":null,"abstract":"<div><h3>Background</h3><div>Isoflurane, a commonly used anesthetic, has been linked to neurocognitive dysfunction (NCD). However, the precise relationship between isoflurane anesthesia and NCD remains unclear.</div></div><div><h3>Methods</h3><div>Datasets related to isoflurane anesthesia were obtained from a public database. The hub genes of isoflurane anesthesia were selected using logistic regression with the least absolute shrinkage and selection operator (LASSO). Human neuroblastoma cell line SH-SY5Y was induced to differentiate into terminal neuron-like cells.</div></div><div><h3>Results</h3><div>The signaling pathways involved in isoflurane anesthesia and NCD were subjected to analysis, resulting in the identification of 35 signaling pathways, including the PI3K/AKT pathway, the AGE-RAGE signaling pathway and the apelin signaling pathway, which were found to be associated with both NCD and isoflurane anesthesia. A total of nine cross-expressed genes (Nfe2l2, Fgf2, Edn1, Spp1, Hmox1, Picalm, Gnb5, Eif2s1 and Gls) were identified between isoflurane anesthesia and NCD. The LASSO logistic regression model was employed to identify three hub genes (Fgf2, Gnb5, Spp1). The expression of these three hub genes was validated using other expression datasets. In human neuron-like cells, isoflurane also significantly affected the expression of three corresponding human homologous genes. The expression trends of these three genes in human cells were consistent with the expression in rat brains after isoflurane treatment, providing further evidence for the rationality of the three hub genes.</div></div><div><h3>Conclusions</h3><div>The present study revealed key candidate genes and related functional signaling pathways through bioinformatics analysis and cell experiments, which may serve as the basis for isoflurane-related NCD.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"132 ","pages":"Article 107582"},"PeriodicalIF":1.3,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143071315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular imaging of excitability difference between alkaloids/salts (nicotine, nicotinic benzoate, caffeine and arecoline hydrobromide) 生物碱/盐类(尼古丁、烟碱苯甲酸盐、咖啡因和氢溴酸槟榔碱)之间兴奋性差异的分子成像。
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-01 DOI: 10.1016/j.vascn.2024.107569
Dawei Yan , Xiaomin Liu , Yihan Gao , Xiaonan Li , Xiabin Chen , Yiting Qian , Saijing Zheng , Yi Shen
Comparison of the excitability of four different alkaloids/salts, including nicotine, nicotinic benzoate, caffeine and arecoline hydrobromide. Based on positron emission tomography (PET) imaging and 18F-Fallypride, a novel technique for measuring alkaloid/salt excitability in SD rats was developed. Different doses and types of alkaloids/salts were administered to the SD rats in a single nebulised inhalation.
The results showed that: (1) PET imaging technology can detect the excitability intensity of SD rats after single inhalation of alkaloids/salts in non-invasive real time and the optimal PET scanning time of four different alkaloids/salts (nicotine, nicotinic benzoate, caffeine and arecoline hydrobromide) were slightly different. (2) The excitatory saturation effect of four alkaloids/salts was observed in SD rats after single inhalation and the saturation effect doses of nicotine, nicotine benzoate, caffeine and arecine hydrobromide were 0.063 mg/kg, 0.075 mg/kg, 0.33 mg/kg and 0.075 mg/kg, respectively. (3) In the case of single inhalation of the same dose of four alkaloids/salts, male SD rats inhaled arecoline hydrobromide with the strongest excitability, while female SD rats inhaled nicotinic benzoate. A PET method for noninvasive real-time detection of alkaloid/salt excitability in SD rats was established.
The finding of an excitatory saturation effect for four alkaloids/salts (nicotine, nicotinic benzoate, caffeine and arecoline hydrobromide) and the presence of excitatory intensity and gender differences at the same dose of inhalation of four alkaloids/salts, which provide a new theoretical basis for determiningthe content of alkaloids/salts.
比较四种不同生物碱/盐(包括尼古丁、烟碱苯甲酸盐、咖啡因和氢溴酸异山豆根碱)的兴奋性。基于正电子发射断层扫描(PET)成像和18F-法利肽,开发了一种测量SD大鼠生物碱/盐兴奋性的新技术。通过一次雾化吸入给 SD 大鼠注射不同剂量和类型的生物碱/盐。结果表明(1)PET成像技术可以无创实时检测SD大鼠单次吸入生物碱/盐类后的兴奋强度,且四种不同生物碱/盐类(尼古丁、苯甲酸烟碱、咖啡因和氢溴酸异丙嗪)的最佳PET扫描时间略有不同。(2)四种生物碱/盐类在 SD 大鼠体内单次吸入后观察到兴奋饱和效应,尼古丁、苯甲酸尼古丁、咖啡因和氢溴酸阿糖胞苷的饱和效应剂量分别为 0.063 mg/kg、0.075 mg/kg、0.33 mg/kg 和 0.075 mg/kg。(3)在单次吸入相同剂量的四种生物碱/盐的情况下,雄性 SD 大鼠吸入氢溴酸苔藓碱的兴奋性最强,而雌性 SD 大鼠吸入苯甲酸烟碱的兴奋性最强。建立了一种 PET 方法,用于无创实时检测 SD 大鼠体内生物碱/盐的兴奋性。发现四种生物碱/盐(烟碱、烟碱苯甲酸盐、咖啡因和氢溴酸异山豆根碱)的兴奋饱和效应,以及在相同剂量吸入四种生物碱/盐时存在兴奋强度和性别差异,为确定生物碱/盐的含量提供了新的理论依据。
{"title":"Molecular imaging of excitability difference between alkaloids/salts (nicotine, nicotinic benzoate, caffeine and arecoline hydrobromide)","authors":"Dawei Yan ,&nbsp;Xiaomin Liu ,&nbsp;Yihan Gao ,&nbsp;Xiaonan Li ,&nbsp;Xiabin Chen ,&nbsp;Yiting Qian ,&nbsp;Saijing Zheng ,&nbsp;Yi Shen","doi":"10.1016/j.vascn.2024.107569","DOIUrl":"10.1016/j.vascn.2024.107569","url":null,"abstract":"<div><div>Comparison of the excitability of four different alkaloids/salts, including nicotine, nicotinic benzoate, caffeine and arecoline hydrobromide. Based on positron emission tomography (PET) imaging and <sup>18</sup>F-Fallypride, a novel technique for measuring alkaloid/salt excitability in SD rats was developed. Different doses and types of alkaloids/salts were administered to the SD rats in a single nebulised inhalation.</div><div>The results showed that: (1) PET imaging technology can detect the excitability intensity of SD rats after single inhalation of alkaloids/salts in non-invasive real time and the optimal PET scanning time of four different alkaloids/salts (nicotine, nicotinic benzoate, caffeine and arecoline hydrobromide) were slightly different. (2) The excitatory saturation effect of four alkaloids/salts was observed in SD rats after single inhalation and the saturation effect doses of nicotine, nicotine benzoate, caffeine and arecine hydrobromide were 0.063 mg/kg, 0.075 mg/kg, 0.33 mg/kg and 0.075 mg/kg, respectively. (3) In the case of single inhalation of the same dose of four alkaloids/salts, male SD rats inhaled arecoline hydrobromide with the strongest excitability, while female SD rats inhaled nicotinic benzoate. A PET method for noninvasive real-time detection of alkaloid/salt excitability in SD rats was established.</div><div>The finding of an excitatory saturation effect for four alkaloids/salts (nicotine, nicotinic benzoate, caffeine and arecoline hydrobromide) and the presence of excitatory intensity and gender differences at the same dose of inhalation of four alkaloids/salts, which provide a new theoretical basis for determiningthe content of alkaloids/salts.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"130 ","pages":"Article 107569"},"PeriodicalIF":1.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-situ polyherbal gel as biomedicine in the management of Alzheimer's disease: Understanding ameliorative potential in Trimethyltin induced neurodegeneration 将原位多草药凝胶作为治疗阿尔茨海默氏症的生物医药:了解三甲基锡诱导的神经变性的改善潜力。
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-10 DOI: 10.1016/j.vascn.2024.107567
Sneha Latha Diddi , Sathiyanarayanan Lohidasan , Arulmozhi S , Vividha Dhapte-Pawar , Kakasaheb R. Mahadik
Alzheimer's disease (AD), classified as neurodegenerative disorder that progresses over a period of time, is characterized by intracellular neurofibrillary tangles and extracellular amyloid plaques. This present research work was designed to develop a polyherbal gel for the treatment of AD. This research study is aimed to confirm the impact and validation of polyherbal gel on tauopathy and neurodegeneration that had been induced by intraperitoneal trimethyltin (TMT) injection to rats.
Polyherbal loaded gel was prepared by cold method, and characterized for gel strength, viscosity, permeation and pH. Subsequently, 5 marker based standardized plant materials of Kalyanka ghrita were incorporated in gellan gum and xanthan gum. Finally, an in-vivo investigation employing rats with TMT-induced neurological disease were used to assess the efficacy of the optimized gel.
On day 7, the Wistar rats received intraperitoneal injections of TMT. From day 14 to day 35, the corresponding groups received intranasal administration of polyherbal gel. In addition to the molecular parameters such as brain acetyl cholinesterase activity, BDNF (Rat brain derived neurotropic factor), protein phosphatase 2 A, antioxidant parameters, and oxidative stress markers, the behavioral parameters were also determined. Studies were conducted on the brain's monoamine levels and histology.

Results

Higher permeation over the nasal mucosa was demonstrated by the optimized In-situ polyherbal gel. Significant improvement in cognition was observed from the reduced escape latency, longer paths, and increased social or novel object recognition tests post polyherbal gel treatment. A documented HPLC technique helped in optimization and standardization of the polyherbal gel. The polyherbal treatment groups exhibited a considerable rise in the levels of monoamines, including norepinephrine, dopamine, and 5-hydroxy tryptamine.

Conclusion

According to the current study, treating Alzheimer's disease (AD) with a polyherbal gel formulation may be a viable option for successful therapy.
阿尔茨海默病(AD)被归类为神经退行性疾病,会在一段时间内发展,其特征是细胞内的神经纤维缠结和细胞外的淀粉样斑块。本研究工作旨在开发一种多草药凝胶,用于治疗 AD。这项研究旨在证实多草本凝胶对大鼠腹腔注射三甲基锡(TMT)诱导的牛头蛋白病和神经退行性变的影响和有效性。多草本凝胶采用冷冻法制备,并对凝胶强度、粘度、渗透性和 pH 值进行了表征。随后,在结冷胶和黄原胶中加入了 5 种基于 Kalyanka ghrita 标准化植物材料的标记物。最后,使用 TMT 诱导的神经系统疾病大鼠进行体内调查,以评估优化凝胶的功效。第 7 天,Wistar 大鼠腹腔注射 TMT。从第 14 天到第 35 天,相应组别接受多草本凝胶的鼻内给药。除了脑乙酰胆碱酯酶活性、BDNF(大鼠脑源性神经营养因子)、蛋白磷酸酶 2 A、抗氧化参数和氧化应激标记物等分子参数外,还测定了行为参数。还对大脑单胺水平和组织学进行了研究。结果:优化后的原位多草药凝胶在鼻粘膜上的渗透性更高。多草药凝胶治疗后,逃逸潜伏期缩短,路径延长,社交或新物体识别测试增加,从而观察到认知能力显著提高。有据可查的高效液相色谱技术有助于多草本凝胶的优化和标准化。多草药治疗组的单胺类物质(包括去甲肾上腺素、多巴胺和 5-羟色胺)水平显著上升。结论:根据目前的研究,用多草本凝胶配方治疗阿尔茨海默病(AD)可能是成功治疗的可行选择。
{"title":"In-situ polyherbal gel as biomedicine in the management of Alzheimer's disease: Understanding ameliorative potential in Trimethyltin induced neurodegeneration","authors":"Sneha Latha Diddi ,&nbsp;Sathiyanarayanan Lohidasan ,&nbsp;Arulmozhi S ,&nbsp;Vividha Dhapte-Pawar ,&nbsp;Kakasaheb R. Mahadik","doi":"10.1016/j.vascn.2024.107567","DOIUrl":"10.1016/j.vascn.2024.107567","url":null,"abstract":"<div><div>Alzheimer's disease (AD), classified as neurodegenerative disorder that progresses over a period of time, is characterized by intracellular neurofibrillary tangles and extracellular amyloid plaques. This present research work was designed to develop a polyherbal gel for the treatment of AD. This research study is aimed to confirm the impact and validation of polyherbal gel on tauopathy and neurodegeneration that had been induced by intraperitoneal trimethyltin (TMT) injection to rats.</div><div>Polyherbal loaded gel was prepared by cold method, and characterized for gel strength, viscosity, permeation and pH. Subsequently, 5 marker based standardized plant materials of <em>Kalyanka ghrita</em> were incorporated in gellan gum and xanthan gum. Finally, an <em>in-vivo</em> investigation employing rats with TMT-induced neurological disease were used to assess the efficacy of the optimized gel.</div><div>On day 7, the Wistar rats received intraperitoneal injections of TMT. From day 14 to day 35, the corresponding groups received intranasal administration of polyherbal gel. In addition to the molecular parameters such as brain acetyl cholinesterase activity, BDNF (Rat brain derived neurotropic factor), protein phosphatase 2 A, antioxidant parameters, and oxidative stress markers, the behavioral parameters were also determined. Studies were conducted on the brain's monoamine levels and histology.</div></div><div><h3>Results</h3><div>Higher permeation over the nasal mucosa was demonstrated by the optimized <em>In-situ</em> polyherbal gel. Significant improvement in cognition was observed from the reduced escape latency, longer paths, and increased social or novel object recognition tests post polyherbal gel treatment. A documented HPLC technique helped in optimization and standardization of the polyherbal gel. The polyherbal treatment groups exhibited a considerable rise in the levels of monoamines, including norepinephrine, dopamine, and 5-hydroxy tryptamine.</div></div><div><h3>Conclusion</h3><div>According to the current study, treating Alzheimer's disease (AD) with a polyherbal gel formulation may be a viable option for successful therapy.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"130 ","pages":"Article 107567"},"PeriodicalIF":1.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of 4 quantification methods for monitoring 16 antidepressant drugs and their metabolites in human plasma by LC-MS/MS 评估用 LC-MS/MS 监测人体血浆中 16 种抗抑郁药物及其代谢物的 4 种定量方法。
IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-09 DOI: 10.1016/j.vascn.2024.107568
Lingjiao Wang , Mengqiang Zhao , Jiao Li , Hongtao Xu , Yang Song , Yuanyuan Zhao , Jing Yu , Chunhua Zhou

Background

Therapeutic drug monitoring for antidepressants (ADs) is vital due to the potentially serious consequences and disputes related to medical events. Therefore, we created a quick and convenient analysis way for separation and quantification of ADs.

Methods

To ensure quantitative stability, we divided the 16 ADs or their metabolites into 4 pools (AD1-AD4), considering the hospital frequency that the clinician prescribed, the physicochemical properties of medicines, and the calibration range of selected ADs. After precipitation with methanol, the analytes were eluted for at least 3.5 min on a BEH C18 analytical column by different gradient elution methods. Results: The LLOQ and LOD were 1.25–10 ng/mL and 0.42–5 ng/mL, respectively. High precision (<12 %) and accuracy (87.07–111.47 %) were demonstrated by quality control samples both within and between days. All the compounds were stable at room temperature and within −80 °C.

Conclusion

The method is of wide clinical and laboratory interest due to simpler sample cleanup, shorter chromatographic run times, and wider calibration range compared to other methods.
背景:抗抑郁药(ADs)的治疗药物监测至关重要,因为它可能造成严重后果,并引发医疗纠纷。因此,我们创建了一种快速、便捷的分析方法来分离和量化抗抑郁药:为了确保定量的稳定性,我们根据临床医生开具处方的医院频率、药物的理化性质以及所选 ADs 的校准范围,将 16 种 ADs 或其代谢物分为 4 个池(AD1-AD4)。分析物经甲醇沉淀后,在 BEH C18 分析柱上用不同的梯度洗脱方法洗脱至少 3.5 分钟:结果:LLOQ 和 LOD 分别为 1.25-10 纳克/毫升和 0.42-5 纳克/毫升。结果:LLOQ 和 LOD 分别为 1.25-10 ng/mL 和 0.42-5 ng/mL:与其他方法相比,该方法样品清理简单、色谱运行时间短、校准范围广,因此受到临床和实验室的广泛关注。
{"title":"Evaluation of 4 quantification methods for monitoring 16 antidepressant drugs and their metabolites in human plasma by LC-MS/MS","authors":"Lingjiao Wang ,&nbsp;Mengqiang Zhao ,&nbsp;Jiao Li ,&nbsp;Hongtao Xu ,&nbsp;Yang Song ,&nbsp;Yuanyuan Zhao ,&nbsp;Jing Yu ,&nbsp;Chunhua Zhou","doi":"10.1016/j.vascn.2024.107568","DOIUrl":"10.1016/j.vascn.2024.107568","url":null,"abstract":"<div><h3>Background</h3><div>Therapeutic drug monitoring for antidepressants (ADs) is vital due to the potentially serious consequences and disputes related to medical events. Therefore, we created a quick and convenient analysis way for separation and quantification of ADs.</div></div><div><h3>Methods</h3><div>To ensure quantitative stability, we divided the 16 ADs or their metabolites into 4 pools (AD1-AD4), considering the hospital frequency that the clinician prescribed, the physicochemical properties of medicines, and the calibration range of selected ADs. After precipitation with methanol, the analytes were eluted for at least 3.5 min on a BEH C<sub>18</sub> analytical column by different gradient elution methods. <strong>Results:</strong> The LLOQ and LOD were 1.25–10 ng/mL and 0.42–5 ng/mL, respectively. High precision (&lt;12 %) and accuracy (87.07–111.47 %) were demonstrated by quality control samples both within and between days. All the compounds were stable at room temperature and within −80 °C.</div></div><div><h3>Conclusion</h3><div>The method is of wide clinical and laboratory interest due to simpler sample cleanup, shorter chromatographic run times, and wider calibration range compared to other methods.</div></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":"130 ","pages":"Article 107568"},"PeriodicalIF":1.3,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of pharmacological and toxicological methods
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1